RGCC International

20/08/2025

Our Founder and Director, Dr. Ioannis Papasotiriou, was featured on "A Healthy Point of View" Podcast with Samael Tejada and Dr. Christopher Davis.

This episode explores how ’s advanced cancer screening tools are transforming early detection and personalized therapy.

📺 Watch the full episode:

In this groundbreaking episode of A Healthy Point of View, host Sam Tejada is joined by the CMO of Liquivida who is an interventional cardiologist, Dr. Chris...

13/08/2025

Have you read our recent study: Evaluation of the effect of benzaldehyde derivatives in human cancer cells?

The study evaluates the effect of a commercial formulation of benzaldehyde and its derivatives on the proliferation of lung and prostate cells.

📈 Read the article and all our published studies here: https://rgcc-international.com/published-articles/

01/08/2025

🫁 Marking 🫁

Lung cancer remains the leading cause of cancer-related deaths worldwide, with over 2.2 million diagnoses and 1.8 million deaths reported in 2020 alone. Often detected too late, lung presents ongoing challenges, but advances in diagnostics, conventional therapies, and personalized approaches are offering new hope.

Our latest patient guide, “Treatment of lung cancer: established methods and new therapy options,” explores current challenges and the evolving landscape of lung cancer care.

🔗 Read it here: rgcc-international.com/patient-information/lung-cancer-therapy/

28/07/2025

Our analytical laboratory in Baar, Switzerland, is equipped with a state-of-the-art 600 MHz Ascend Bruker Avance III HD system with a BBFO Probe. This setup allows us to perform high-sensitivity NMR testing on a wide array of nuclei and utilize advanced decoupling capabilities.

Visit our website to see examples of the reports we provide, including:
🧪 1D experiments
🧪 2D experiements
🧪 qNMR

Learn more >> rgcc-international.com/nmr/

-

24/07/2025

The Onconomics panel consists of four tests that help clinicians address critical questions about characteristics, aiding in more informed treatment decisions. By evaluating cell sensitivity and resistance to various therapies, the Onconomics panel ensures that treatment plans are grounded in precise, personalized data.
🔗 Learn more: rgcc-international.com/tests/

16/07/2025

According to the World Health Organization (WHO), up to 50% of cancers could be prevented by addressing known risk factors, such as avoiding to***co, maintaining a healthy weight, staying active, and following a balanced diet.

While prevention is critical, early detection plays an equally important role. Cancers identified at an early stage are often more treatable and associated with better outcomes and lower healthcare costs.

At , we contribute to this effort through tools like Onco-D-clare, a screening test designed to support early diagnosis, sometimes even before symptoms appear.

Raising awareness, advancing diagnostics, and supporting informed decisions are all essential in the fight against .

🔍 Learn more about Onco-D-clare: https://rgcc-international.com/tests/

10/07/2025

Last week, our collaborator Ana Paz presented RGCC’s latest research at the ESMO - European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 in Barcelona, Spain.
The e-poster, titled "Enumeration and Immunophenotype of Circulating Tumor Cells in Colorectal Patients", highlights the potential of using circulating tumor cell ( ) count and protein expression data to improve monitoring in colorectal cancer (CRC). While the findings suggest promising applications, the study also emphasizes the need for deeper investigation into specific expression patterns and their clinical significance in CRC.
The congress brought together leading experts, researchers and healthcare professionals dedicated to advancing Gastrointestinal cancer diagnostics and treatment, an inspiring platform to share ’s growing contributions to the field.
📚 Explore the e-poster and all RGCC studies here: rgcc-international.com/published-articles/

08/07/2025

A powerful reflection from Dr. Christine Stueve, Founder of NSIPM and Sano Consulting and Wellness Center (USA), who shares her experience with RGCC’s approach to cancer care.

At , we’re committed to supporting healthcare practitioners and their patients with advanced, personalised diagnostics and scientific innovation.

💬 Discover more testimonials from patients and healthcare professionals: rgcc-international.com/testimonials

04/07/2025

🎥 Throwback to the 2023 Gathering in Zurich, Switzerland.

Dr. Herbert Schäffer reflects on his firsthand encounters with our technologies in treatment. In this enlightening video, Dr. Schäffer shares insights into how these innovative approaches have impacted his clinical practice.

Embark on a transformative journey with Dr. Herbert Schäffer as he delves into his firsthand encounters with cutting-edge RGCC technologies in cancer treatme...

01/07/2025

How does InVyomma Plus, 's latest test, work?

✔️ It integrates Next Generation Sequencing with advanced bioinformatics algorithms.
✔️ It integrates the results with a sophisticated algorithm and an expanding database that maps how microbes interact with the human body.
✔️ It measures short-chain fatty acids in stool samples, offering deeper insights into the bacterial balance and activity.

For more information about InVyomma Plus and RGCC’s full range of diagnostic tests, visit: rgcc-international.com/tests/invyomma-plus/

25/06/2025

What is the optimal second-line treatment for advanced pancreatic cancer? Despite ongoing research, this critical question remains unanswered.
Our latest published study explores the potential of circulating cells (CTCs) to guide second-line chemotherapy decisions in advanced pancreatic , offering a personalized approach.
📄 Read the study: https://rgcc-international.com/published-articles/

20/06/2025

We’re excited to announce the launch of the official website for Welmedis, RGCC’s sister company dedicated to advancing personalized cancer treatment.

Welmedis aims to transform cancer care by developing targeted therapeutics. Using gene and protein expression data from the RGCC target identification pipeline, the Welmedis team identifies novel targets for small-molecule therapeutics tailored to specific patient populations. This innovative approach combines cutting-edge diagnostics and drug development to provide the most effective treatments for specific cancer types.

This launch represents a powerful extension of our shared mission: to drive progress in precision medicine and improve outcomes for cancer patients worldwide.

🔗 Explore the new site and learn more about how Welmedis is helping shape the future of oncology:

We deliver personalized cancer treatments powered by diagnostic insights. Discover more about our mission and our cutting-edge work.